Until recently, the only therapy proven to improve outcomes for all ischemic stroke patients was the intravenous (IV) administration of tissue plasminogen activator (tPA), which can be administered up to 4.5 h from the onset of symptoms or when the patient was last known normal. Here, PLAT is linked to ischemic stroke.